US 2013/0251718 A1 · ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES

Abstract

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

Claims4

Dependent claims

1-49. (canceled)

A method of treating an IL-4 and/or IL-13 mediated disease in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a bispecific antibody or bispecific antibody fragment thereof that specifically binds to IL-13 and IL-4,

wherein the bispecific antibody or bispecific antibody fragment thereof comprises a first pair of polypeptides and a second pair of polypeptides;
wherein the first pair of polypeptides comprise an outer (N-terminal) variable light chain domain linked to an inner (C-terminal) variable light chain domain which is linked to a constant light chain domain (CL), and the second pair of polypeptides comprise an outer (N-terminal) variable heavy chain domain linked to an inner (C-terminal) variable heavy chain domain which is linked to a constant heavy chain domain (CH1);
and
wherein:
(a) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-13, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-4, or
(b) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-4, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-13;
and wherein the bispecific antibody or bispecific antibody fragment thereof binds the same epitope or epitopes on IL-13 and/or IL-4 as:
(i) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2;
(ii) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13);
(iii) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3, and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4;
(iv) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(v) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
17 IDPSDGETR (SEQ ID NO:
18) and LKEYGNYDSFYFDV SE ID NO:
19);
(vi) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV SE ID NO:
22);
(vii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2, and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4:
(viii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SE ID NO:
2 and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(ix) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16), GYSFTSYWIH (SEQ ID NO:
17), IDPSDGETR (SEQ ID NO:
18), and LKEYGNYDSFYFDV (SEQ ID NO:
19);
or
(x) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV (SEQ ID NO:
22).

71 more elements

A method of suppressing a TH-2 mediated response in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a bispecific antibody or bispecific antibody fragment thereof that specifically binds to IL-13 and IL-4,

wherein the bispecific antibody or bispecific antibody fragment thereof comprises a first pair of polypeptides and a second pair of polypeptides;
wherein the first pair of polypeptides comprise an outer (N-terminal) variable light chain domain linked to an inner (C-terminal) variable light chain domain which is linked to a constant light chain domain (CL), and the second pair of polypeptides comprise an outer (N-terminal) variable heavy chain domain linked to an inner (C-terminal) variable heavy chain domain which is linked to a constant heavy chain domain (CH1);
and
wherein:
(a) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-13, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-4, or
(b) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-4, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-13;
and wherein the bispecific antibody or bispecific antibody fragment thereof binds the same epitope or epitopes on IL-13 and/or IL-4 as:
(i) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2;
(ii) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13);
(iii) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3, and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4;
(iv) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(v) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
17), IDPSDGETR (SEQ ID NO:
18) and LKEYGNYDSFYFDV SE ID NO:
19);
(vi) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV SE ID NO:
22);
(vii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2 and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4;
(viii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2 and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(ix) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16), GYSFTSYWIH (SEQ ID NO:
17), IDPSDGETR (SEQ ID NO:
18), and LKEYGNYDSFYFDV (SEQ ID NO:
19);
or
(x) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16), GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV (SEQ ID NO:
22).

71 more elements

Dependencies are inferred from the claim text.

Facts

Application

13/794,384Filed 11 Mar 2013

Priority

EP 07291259.515 Oct 2007

Published

26 Sep 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07K 16/468
Hybrid immunoglobulins: immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
A61P 11/00
Drugs for disorders of the respiratory system
A61P 11/06
Drugs for disorders of the respiratory system: antiasthmatics
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents

Family

Application61/037,128Us provisional application · filed 17 Mar 2008

Application12/682,864Continuation · filed 13 Apr 2010

Application13/758,858Continuation · filed 4 Feb 2013

Application13/794,384Continuation

US 2010/0226923 A1Published application

US 2013/0209469 A1Published application

US 8,388,965 B2Related patent

US 2013/0251718 A1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Claims4

Dependent claims

1-49. (canceled)

wherein the bispecific antibody or bispecific antibody fragment thereof comprises a first pair of polypeptides and a second pair of polypeptides;
wherein the first pair of polypeptides comprise an outer (N-terminal) variable light chain domain linked to an inner (C-terminal) variable light chain domain which is linked to a constant light chain domain (CL), and the second pair of polypeptides comprise an outer (N-terminal) variable heavy chain domain linked to an inner (C-terminal) variable heavy chain domain which is linked to a constant heavy chain domain (CH1);
and
wherein:
(a) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-13, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-4, or
(b) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-4, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-13;
and wherein the bispecific antibody or bispecific antibody fragment thereof binds the same epitope or epitopes on IL-13 and/or IL-4 as:
(i) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2;
(ii) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13);
(iii) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3, and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4;
(iv) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(v) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
17 IDPSDGETR (SEQ ID NO:
18) and LKEYGNYDSFYFDV SE ID NO:
19);
(vi) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV SE ID NO:
22);
(vii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2, and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4:
(viii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SE ID NO:
2 and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(ix) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16), GYSFTSYWIH (SEQ ID NO:
17), IDPSDGETR (SEQ ID NO:
18), and LKEYGNYDSFYFDV (SEQ ID NO:
19);
or
(x) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV (SEQ ID NO:
22).

71 more elements

wherein the bispecific antibody or bispecific antibody fragment thereof comprises a first pair of polypeptides and a second pair of polypeptides;
wherein the first pair of polypeptides comprise an outer (N-terminal) variable light chain domain linked to an inner (C-terminal) variable light chain domain which is linked to a constant light chain domain (CL), and the second pair of polypeptides comprise an outer (N-terminal) variable heavy chain domain linked to an inner (C-terminal) variable heavy chain domain which is linked to a constant heavy chain domain (CH1);
and
wherein:
(a) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-13, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-4, or
(b) the outer (N-terminal) variable light chain domain and outer (N-terminal) variable heavy chain domain form an outer (N-terminal) antigen-binding site that specifically binds IL-4, and the inner (C-terminal) variable light chain domain and the inner (C-terminal) variable heavy chain domain form an inner (C-terminal) antigen-binding site that specifically binds IL-13;
and wherein the bispecific antibody or bispecific antibody fragment thereof binds the same epitope or epitopes on IL-13 and/or IL-4 as:
(i) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2;
(ii) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13);
(iii) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3, and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4;
(iv) an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(v) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
17), IDPSDGETR (SEQ ID NO:
18) and LKEYGNYDSFYFDV SE ID NO:
19);
(vi) an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16 GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV SE ID NO:
22);
(vii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2 and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
4;
(viii) an anti-IL-13 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
1 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
2 and an anti-IL-4 antibody or antibody fragment thereof that comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO:
3 and a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO:
5;
(ix) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16), GYSFTSYWIH (SEQ ID NO:
17), IDPSDGETR (SEQ ID NO:
18), and LKEYGNYDSFYFDV (SEQ ID NO:
19);
or
(x) an anti-IL-13 antibody or antibody fragment thereof that comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO:
8), LASNLES (SEQ ID NO:
9), QQNAEDSRT (SEQ ID NO:
10), GFSLTDSSIN (SEQ ID NO:
11), DGRID (SEQ ID NO:
12), and DGYFPYAMDF (SEQ ID NO:
13), and an anti-IL-4 antibody or antibody fragment thereof that comprises the amino acid sequences of HASQNIDVWLS (SEQ ID NO:
14), KASNLHTG (SEQ ID NO:
15), QQAHSYPFT (SEQ ID NO:
16), GYSFTSYWIH (SEQ ID NO:
20), IDASDGETR (SEQ ID NO:
21), and LKEYGNYDSFYFDV (SEQ ID NO:
22).

71 more elements

Dependencies are inferred from the claim text.

Antibodies that bind il-4 and/or il-13 and their uses

Life of this patent

Abstract

Claims4

Antibodies that bind il-4 and/or il-13 and their uses

Life of this patent

Abstract

Claims4